Compare AX & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AX | MRUS |
|---|---|---|
| Founded | 1999 | 2003 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 5.1B |
| IPO Year | 2005 | 2016 |
| Metric | AX | MRUS |
|---|---|---|
| Price | $82.19 | $96.01 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 17 |
| Target Price | ★ $96.86 | $94.94 |
| AVG Volume (30 Days) | 266.1K | ★ 1.3M |
| Earning Date | 10-30-2025 | 10-31-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.44 | N/A |
| Revenue | ★ $1,202,571,000.00 | $56,606,000.00 |
| Revenue This Year | $17.36 | $52.81 |
| Revenue Next Year | $10.34 | N/A |
| P/E Ratio | $11.06 | ★ N/A |
| Revenue Growth | 6.69 | ★ 57.54 |
| 52 Week Low | $54.46 | $33.19 |
| 52 Week High | $93.84 | $96.28 |
| Indicator | AX | MRUS |
|---|---|---|
| Relative Strength Index (RSI) | 55.13 | 69.40 |
| Support Level | $81.48 | $95.74 |
| Resistance Level | $83.43 | $96.19 |
| Average True Range (ATR) | 2.29 | 0.36 |
| MACD | 0.59 | -0.36 |
| Stochastic Oscillator | 83.01 | 60.87 |
Axos Financial Inc is a bank holding company that operates through its bank subsidiary, BofI Federal Bank, a nationwide bank that provides financing for single and multifamily residential properties, small to medium-size businesses in certain sectors, and selected specialty finance receivables. Its operating segments are banking business segment and securities business segment. The bank distributed its products through a wide range of retail distribution channels, including only banking brands, affinity groups, and sales teams, among others. The majority of the bank's mortgage exposure is titled toward the state of California, particularly its southern region. Net interest income is a majority of the bank's revenue.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.